Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1456 to 1470 of 2208 results for guidelines

  1. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

  2. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

  3. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTG674)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.

  4. National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)

    NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .

  5. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  6. Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.

  7. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.

  8. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

  9. What is the relative effectiveness and cost effectiveness of different oral fluids and different oral fluid regimens, both with and without oral N-acetylcysteine, at preventing contrast-induced acute kidney injury?

    factors were taken from recommendation 1.1.6 (developed as part of the 2013 guideline) apart from the level of eGFR which was based on...

  10. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    prescribed for sciatica. They noted that advice is already included in this guideline for the use of paracetamol for people with low...

  11. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    prescribed for sciatica. They noted that advice is already included in this guideline for the use of paracetamol for people with low...

  12. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

  13. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

  14. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

  15. Stakeholder registration - confidentiality agreement

    This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information